Brokerages expect PetIQ Inc (NASDAQ:PETQ) to announce $125.09 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for PetIQ’s earnings. The highest sales estimate is $128.40 million and the lowest is $121.10 million. PetIQ posted sales of $60.55 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 106.6%. The business is expected to announce its next quarterly earnings results on Monday, November 5th.

According to Zacks, analysts expect that PetIQ will report full year sales of $501.83 million for the current fiscal year, with estimates ranging from $495.10 million to $505.30 million. For the next fiscal year, analysts forecast that the business will report sales of $578.65 million per share, with estimates ranging from $550.00 million to $596.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover PetIQ.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Tuesday, August 14th. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $171.10 million during the quarter, compared to analysts’ expectations of $148.48 million. PetIQ had a positive return on equity of 11.40% and a negative net margin of 0.76%. The business’s revenue for the quarter was up 96.2% on a year-over-year basis.

A number of analysts recently commented on PETQ shares. SunTrust Banks upped their price objective on PetIQ to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 15th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price target on shares of PetIQ in a report on Wednesday, May 16th. Zacks Investment Research raised PetIQ from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. BidaskClub raised PetIQ from a “sell” rating to a “hold” rating in a report on Friday, May 25th. Finally, ValuEngine raised PetIQ from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $33.33.

PetIQ stock opened at $38.65 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of 99.10, a PEG ratio of 2.10 and a beta of 0.37. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.00 and a quick ratio of 0.90. PetIQ has a one year low of $17.03 and a one year high of $41.89.

In other PetIQ news, CEO Mccord Christensen sold 13,652 shares of the business’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $23.00, for a total transaction of $313,996.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Will Santana sold 20,000 shares of the business’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $27.14, for a total value of $542,800.00. The disclosure for this sale can be found here. Insiders have sold 242,974 shares of company stock valued at $7,930,882 in the last three months. 45.26% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in PetIQ by 64.0% during the first quarter. The Manufacturers Life Insurance Company now owns 6,838 shares of the company’s stock valued at $182,000 after purchasing an additional 2,669 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in PetIQ by 29.1% during the first quarter. Schwab Charles Investment Management Inc. now owns 16,400 shares of the company’s stock valued at $437,000 after purchasing an additional 3,700 shares during the period. GSA Capital Partners LLP boosted its stake in shares of PetIQ by 38.1% in the second quarter. GSA Capital Partners LLP now owns 19,200 shares of the company’s stock worth $516,000 after acquiring an additional 5,300 shares during the period. Creative Planning boosted its stake in shares of PetIQ by 64.3% in the second quarter. Creative Planning now owns 14,015 shares of the company’s stock worth $376,000 after acquiring an additional 5,485 shares during the period. Finally, NJ State Employees Deferred Compensation Plan boosted its stake in shares of PetIQ by 13.0% in the second quarter. NJ State Employees Deferred Compensation Plan now owns 52,000 shares of the company’s stock worth $1,397,000 after acquiring an additional 6,000 shares during the period. 77.30% of the stock is owned by institutional investors and hedge funds.

PetIQ Company Profile

PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Featured Story: What are CEFs?

Get a free copy of the Zacks research report on PetIQ (PETQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.